We are pleased to announce that The Arcady Group has had two contracts with the Gates Foundation extended and supplemented. Additionally, our work on new, innovative technologies to combat the growing threat of dengue is entering an exciting new phase.
Under the first contract, now extended through November 30, 2026, The Arcady Group will continue providing strategic, cost-effective chemistry, manufacturing, and controls (CMC) consulting to the Gates Foundation, supporting drug products designed for global health applications. The second contract, extended and supplemented through December 31, 2025, enables us to further address affordability and dosing complexity challenges for potential PAN-TB regimens, helping to ensure these treatments remain accessible and affordable in resource-limited settings.
Additionally, The Arcady Group’s work on Wolbachia Replacement Technology (WRT)—a cutting-edge vector control solution to combat dengue—continues. Since 2018, we have provided subject matter expertise to the Gates Foundation, supporting the evaluation and cost-effective scale-up of WRT. Our contributions include:
- Assisting a Technical Advisory Group established by the World Health Organization in developing a Target Product Profile for WRT.
- Supporting the Gates Foundation in its work to scale-up WRT, ultimately leading to a grant to Oxitec, Ltd., a global leader in biological pest control solutions.
- With the Gates Foundation’s permission, providing ongoing assistance to Oxitec in its efforts to deliver affordable WRT solutions at a global scale.
2025 marks the 11th year that The Arcady Group has been working with global health organizations like the Gates Foundation to reduce infectious disease morbidity and mortality in resource-limited settings. It has been a privilege and, for those of us who are now or have been part of The Arcady Group, a highlight of our professional careers.